{"nctId":"NCT02189837","briefTitle":"Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody","startDateStruct":{"date":"2014-07-08","type":"ACTUAL"},"conditions":["Primary Hyperlipidemia and Mixed Dyslipidemia"],"count":89,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo to Evolocumab","Drug: Placebo to Atorvastatin"]},{"label":"Atorvastatin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Atorvastatin","Drug: Placebo to Evolocumab"]},{"label":"Evolocumab","type":"EXPERIMENTAL","interventionNames":["Biological: Evolocumab","Drug: Placebo to Atorvastatin"]},{"label":"Evolocumab and Atorvastatin","type":"EXPERIMENTAL","interventionNames":["Biological: Evolocumab","Drug: Atorvastatin"]}],"interventions":[{"name":"Evolocumab","otherNames":["AMG 145","Repatha"]},{"name":"Atorvastatin","otherNames":["LIPITOR®"]},{"name":"Placebo to Evolocumab","otherNames":[]},{"name":"Placebo to Atorvastatin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Fasting LDL-C at screening ≥ 100 mg/dL and ≤ 190 mg/dL\n* Fasting triglycerides ≤ 150 mg/dL\n* Body mass index (BMI) between 18.0 and 32.0 kg/m\\^2\n* Framingham cardiac risk score 10% or less\n\nExclusion Criteria:\n\n* Treatment with a lipid-regulating drug or over the counter supplement in the last 3 months prior to screening\n* History of coronary heart disease (CHD) or CHD equivalent\n* Uncontrolled hypertension\n* Diabetes mellitus","healthyVolunteers":true,"sex":"MALE","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Low-density Lipoprotein (LDL) Apolipoprotein B-100 Fractional Catabolic Rate (FCR)","description":"The fractional catabolic rate (the percentage of apolipoprotein B-100 in LDL which is replaced, transferred or lost per unit of time) was measured at Baseline and Day 50 over 5 consecutive days using the stable isotope tracer, D3-leucine. LDL particles were isolated from plasma by sequential ultracentrifugation, and isotopic enrichment was determined using gas chromatography-mass spectrometry. Mathematical modelling of the protein enrichment data was used to estimate protein catabolism.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.07","spread":"26.06"},{"groupId":"OG001","value":"74.13","spread":"24.84"},{"groupId":"OG002","value":"83.70","spread":"26.06"},{"groupId":"OG003","value":"310.48","spread":"26.68"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in LDL-C at Day 50","description":"LDL-C was measured using ultrcentrifugation.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.65","spread":"3.09"},{"groupId":"OG001","value":"-45.25","spread":"2.86"},{"groupId":"OG002","value":"-57.79","spread":"3.15"},{"groupId":"OG003","value":"-83.19","spread":"3.24"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in LDL Apolipoprotein B-100 Production Rate (PR)","description":"The production rate of apolipoprotein B-100 in LDL was measured at Baseline and Day 50 over 5 consecutive days using the stable isotope tracer, D3-leucine. LDL particles were isolated from plasma by sequential ultracentrifugation and isotopic enrichment was determined using gas chromatography-mass spectrometry. Mathematical modelling of the protein enrichment data was used to estimate the production rate.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.80","spread":"7.40"},{"groupId":"OG001","value":"-3.27","spread":"7.05"},{"groupId":"OG002","value":"-20.45","spread":"7.40"},{"groupId":"OG003","value":"-35.93","spread":"7.57"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lipoprotein (a) Fractional Catabolic Rate (FCR)","description":"The fractional catabolic rate (the percentage of lipoprotein(a) (Lp\\[a\\]) which is replaced, transferred or lost per unit of time) was measured at Baseline and Day 50 over 5 consecutive days using the stable isotope tracer, D3-leucine. Lp(a) was isolated from plasma using an immunoprecipitation method employing immunomagnetic beads and polyacrylamide gel electrophoresis. Isotopic enrichment was determined using gas chromatography-mass spectrometry. Mathematical modelling of the protein enrichment data was used to estimate protein catabolism.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.49","spread":"9.17"},{"groupId":"OG001","value":"25.52","spread":"8.92"},{"groupId":"OG002","value":"5.37","spread":"9.81"},{"groupId":"OG003","value":"64.57","spread":"9.23"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lipoprotein(a) Production Rate (PR)","description":"The production rate of lipoprotein(a) was measured at Baseline and Day 50 over 5 consecutive days using the stable isotope tracer, D3-leucine. Lp(a) was isolated from plasma using an immunoprecipitation method employing immunomagnetic beads and polyacrylamide gel electrophoresis. Isotopic enrichment was determined using gas chromatography-mass spectrometry. Mathematical modelling of the protein enrichment data was used to estimate protein catabolism.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.52","spread":"7.94"},{"groupId":"OG001","value":"-6.88","spread":"7.72"},{"groupId":"OG002","value":"-35.91","spread":"8.49"},{"groupId":"OG003","value":"16.40","spread":"7.99"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":21},"commonTop":["Headache","Nausea","Nasopharyngitis","Myalgia","Abdominal pain"]}}}